Compendia Conflict Of Interest White Paper A Precursor To New Regulations
Executive Summary
Compendia publishers can expect to see new regulations regarding transparency and conflict of interest by the end of the year, and those rules could have an effect on whether a compendium will be recognized by CMS as a source for making coverage decisions for off-label drug uses
You may also be interested in...
CMS Proposes Compendia Publish All Materials Related To Listing Decision
In an effort to increase the transparency in the compendia listing process, CMS is proposing that approved compendia publish all materials used in evaluating an off-label usage of a drug
CMS Proposes Compendia Publish All Materials Related To Listing Decision
In an effort to increase the transparency in the compendia listing process, CMS is proposing that approved compendia publish all materials used in evaluating an off-label usage of a drug
Insurers Call For Greater Transparency In Compendia Process
Third-party payers are looking for greater transparency in the processes that are used to generate compendia that list off-label uses of pharmaceuticals